Fortress Biotech, Inc. (FBIO) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
40/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseFBIO / S&P 9.68% / 15.20% |
WinFBIO / S&P 20.68% / 15.00% |
LoseFBIO / S&P -351.43% / 50.40% |
| 2026-Q11/3 |
LoseFBIO / S&P -23.77% / -4.33% |
WinFBIO / S&P 15.89% / 11.30% |
LoseFBIO / S&P -242.15% / 27.70% |
| 2025-Q41/3 |
LoseFBIO / S&P -1.08% / 2.65% |
WinFBIO / S&P 11.07% / 9.00% |
LoseFBIO / S&P -95.34% / 13.40% |
| 2025-Q31/3 |
WinFBIO / S&P 98.92% / 8.12% |
LoseFBIO / S&P 0.04% / 4.61% |
LoseFBIO / S&P -94.12% / 13.45% |
| 2025-Q21/3 |
WinFBIO / S&P 19.23% / 10.94% |
LoseFBIO / S&P -5.18% / 4.83% |
LoseFBIO / S&P -67.59% / 10.63% |
| 2025-Q10/3 |
LoseFBIO / S&P -23.15% / -4.27% |
LoseFBIO / S&P -8.73% / 4.98% |
LoseFBIO / S&P -63.80% / 10.57% |
| 2024-Q41/3 |
WinFBIO / S&P 40.00% / 2.41% |
LoseFBIO / S&P -7.59% / 5.25% |
LoseFBIO / S&P -47.65% / 6.15% |
| 2024-Q30/3 |
LoseFBIO / S&P -15.20% / 5.89% |
LoseFBIO / S&P -4.24% / 5.89% |
LoseFBIO / S&P -68.19% / 6.11% |
| 2024-Q20/3 |
LoseFBIO / S&P -14.50% / 4.28% |
LoseFBIO / S&P -4.37% / 5.38% |
LoseFBIO / S&P -74.67% / 5.12% |
| 2024-Q10/3 |
LoseFBIO / S&P -33.55% / 10.56% |
LoseFBIO / S&P -2.95% / 5.71% |
LoseFBIO / S&P -34.47% / 5.59% |
| 2023-Q40/3 |
LoseFBIO / S&P -30.80% / 11.69% |
LoseFBIO / S&P -15.96% / 6.81% |
LoseFBIO / S&P -43.12% / 7.78% |
| 2023-Q31/3 |
LoseFBIO / S&P -47.27% / -3.27% |
LoseFBIO / S&P -16.90% / 7.52% |
WinFBIO / S&P 95.13% / -5.03% |
| 2023-Q21/3 |
LoseFBIO / S&P -32.93% / 8.74% |
LoseFBIO / S&P -19.79% / 9.50% |
WinFBIO / S&P 1084.26% / -8.57% |
| 2023-Q12/3 |
WinFBIO / S&P 24.24% / 7.50% |
LoseFBIO / S&P -14.82% / 10.77% |
WinFBIO / S&P 993.02% / -15.69% |
| 2022-Q42/3 |
LoseFBIO / S&P -23.26% / 7.56% |
WinFBIO / S&P 12.45% / 11.88% |
WinFBIO / S&P 1086.08% / -17.99% |
| 2022-Q32/3 |
WinFBIO / S&P 2.38% / -4.88% |
WinFBIO / S&P 22.33% / 13.47% |
LoseFBIO / S&P FBIO unavailable / -1.41% |
| 2022-Q21/3 |
LoseFBIO / S&P -38.24% / -16.10% |
WinFBIO / S&P 54.87% / 13.71% |
LoseFBIO / S&P FBIO unavailable / 11.04% |
| 2022-Q11/3 |
LoseFBIO / S&P -45.60% / -4.60% |
WinFBIO / S&P 69.06% / 15.97% |
LoseFBIO / S&P FBIO unavailable / 42.23% |
| 2021-Q41/3 |
LoseFBIO / S&P -22.36% / 11.03% |
WinFBIO / S&P 41.78% / 15.00% |
LoseFBIO / S&P FBIO unavailable / 96.40% |
| 2021-Q31/3 |
LoseFBIO / S&P -9.80% / 0.58% |
WinFBIO / S&P 41.58% / 10.77% |
LoseFBIO / S&P FBIO unavailable / 69.42% |
| 2021-Q21/3 |
LoseFBIO / S&P 1.13% / 8.55% |
WinFBIO / S&P 17.21% / 6.58% |
LoseFBIO / S&P FBIO unavailable / 51.81% |
| 2021-Q12/3 |
WinFBIO / S&P 11.36% / 6.17% |
WinFBIO / S&P 6.29% / -1.06% |
LoseFBIO / S&P FBIO unavailable / 7.39% |
| 2020-Q41/3 |
LoseFBIO / S&P -21.53% / 12.15% |
WinFBIO / S&P 27.52% / -3.72% |
LoseFBIO / S&P FBIO unavailable / -33.42% |
| 2020-Q32/3 |
WinFBIO / S&P 50.75% / 8.93% |
WinFBIO / S&P 40.53% / -2.04% |
LoseFBIO / S&P FBIO unavailable / -27.10% |
| 2020-Q22/3 |
WinFBIO / S&P 41.80% / 20.54% |
WinFBIO / S&P 64.53% / -0.46% |
LoseFBIO / S&P FBIO unavailable / -27.11% |
| 2020-Q11/3 |
LoseFBIO / S&P -26.46% / -19.60% |
WinFBIO / S&P 69.81% / 3.47% |
LoseFBIO / S&P FBIO unavailable / -14.75% |
| 2019-Q42/3 |
WinFBIO / S&P 82.27% / 9.07% |
WinFBIO / S&P 49.39% / 5.36% |
LoseFBIO / S&P FBIO unavailable / 2.99% |
| 2019-Q30/3 |
LoseFBIO / S&P -6.00% / 1.70% |
LoseFBIO / S&P -127.27% / 5.02% |
LoseFBIO / S&P FBIO unavailable / 0.21% |
| 2019-Q20/3 |
LoseFBIO / S&P -15.73% / 4.30% |
LoseFBIO / S&P -137.69% / 6.64% |
LoseFBIO / S&P FBIO unavailable / 8.65% |
| 2019-Q11/3 |
WinFBIO / S&P 106.98% / 13.65% |
LoseFBIO / S&P -201.43% / 8.12% |
LoseFBIO / S&P FBIO unavailable / 14.29% |
| 2018-Q41/3 |
LoseFBIO / S&P -46.25% / -13.52% |
WinFBIO / S&P 50.62% / 9.05% |
LoseFBIO / S&P FBIO unavailable / 18.23% |
| 2018-Q30/3 |
LoseFBIO / S&P -46.31% / 7.71% |
LoseFBIO / S&P -170.62% / 10.21% |
LoseFBIO / S&P FBIO unavailable / 19.06% |
| 2018-Q20/3 |
LoseFBIO / S&P -34.51% / 3.43% |
LoseFBIO / S&P -162.09% / 9.03% |
LoseFBIO / S&P FBIO unavailable / 14.46% |
| 2018-Q11/3 |
WinFBIO / S&P 14.04% / -0.76% |
LoseFBIO / S&P -139.09% / 7.68% |
LoseFBIO / S&P FBIO unavailable / 12.46% |
| 2017-Q40/3 |
LoseFBIO / S&P -9.73% / 6.64% |
LoseFBIO / S&P -5.83% / 7.03% |
LoseFBIO / S&P FBIO unavailable / 13.82% |
| 2017-Q31/3 |
LoseFBIO / S&P -6.95% / 4.48% |
WinFBIO / S&P 3584.99% / 5.68% |
LoseFBIO / S&P FBIO unavailable / 17.57% |
| 2017-Q22/3 |
WinFBIO / S&P 28.38% / 3.09% |
WinFBIO / S&P 3249.80% / 4.83% |
LoseFBIO / S&P FBIO unavailable / 17.74% |
| 2017-Q12/3 |
WinFBIO / S&P 37.04% / 6.07% |
WinFBIO / S&P 5814.17% / 3.67% |
LoseFBIO / S&P FBIO unavailable / 13.32% |
| 2016-Q41/3 |
LoseFBIO / S&P -9.09% / 3.82% |
WinFBIO / S&P 1809.62% / 2.09% |
LoseFBIO / S&P FBIO unavailable / 7.05% |
| 2016-Q32/3 |
WinFBIO / S&P 10.41% / 3.85% |
WinFBIO / S&P 700.57% / 0.20% |
LoseFBIO / S&P FBIO unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | FBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 8.53% | 20.78% |
| Annualized return | 8.53% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | FBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -94.49% | 83.14% |
| Annualized return | -44.00% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | FBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -93.16% | 319.30% |
| Annualized return | -23.53% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |